International Journal of Rheumatic Diseases最新文献

{"title":"Anticytokine (Ligand) Antibody Versus Antireceptor Antibody in Treating Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases","authors":"Hideto Kameda, Reina Maezawa, Yasuto Minegishi, Chihiro Imaizumi, Takehisa Ogura","doi":"10.1111/1756-185X.70202","DOIUrl":"https://doi.org/10.1111/1756-185X.70202","url":null,"abstract":"<p>Intracellular signaling through specific ligand-receptor interactions on the cellular membrane is essential for network communication among various immune cells in immune-mediated inflammatory diseases (IMIDs) [<span>1</span>]. Therapeutic agents extracellularly inhibit this signaling through biological agents and intracellular inhibition via synthetic compounds such as kinase inhibitors (Figure 1). Although the differences between biological agents and kinase inhibitors, as well as among targeted cytokines, have been widely discussed, comparisons between anticytokines (ligands) and antireceptor antibodies remain limited.</p><p>Interleukin-6 (IL-6) inhibition is an example of a distinction between these antibodies. The discovery and cDNA cloning of IL-6 and its receptor, as well as the signaling molecule glycoprotein 130 (gp130), have been pivotal for the successful management of various IMIDs through the inhibition of IL-6 signaling [<span>2</span>]. Tocilizumab, an anti-IL-6 receptor (IL-6R) antibody, was first developed in Japan and approved for the treatment of Castleman disease in 2005, followed by rheumatoid arthritis (RA) and juvenile idiopathic arthritis (both polyarticular and systemic) in 2008. Tocilizumab has been globally approved for various IMIDs, including giant cell arteritis and chimeric antigen receptor (CAR) T-cell-induced cytokine release syndrome [<span>3</span>].</p><p>The subsequent development of biological agents targeting IL-6R, such as sarilumab, and those targeting IL-6 ligands, including sirukumab, clazakizumab, and olokizumab, has provided valuable insights into the difference between anticytokine and antireceptor antibodies [<span>3</span>]. RA treatment with sarilumab has been successful in clinical trials [<span>4-8</span>], with acceptable safety profiles identified through postmarketing surveillance [<span>9, 10</span>]. However, the clinical development of biological agents targeting IL-6 ligands presents several challenges [<span>3</span>].</p><p>The most notable difference between anti-IL-6 and anti-IL-6R blockades lies in the efficiency of neutralizing the target functions within the selected dosing regimens. In our Japanese cohort, the median (interquartile range) serum IL-6 and IL-6R concentrations in treatment-naïve patients with RA were 4.70 (1.51–8.54) pg/mL and 84.2 (62.2–98.0) ng/mL, respectively [<span>11</span>]. Similarly, an RA study in Poland reported median (range) serum IL-6 and IL-6R concentrations of 34.1 (1.5–234.0) pg/mL and 45.366 (17.288–81.760) ng/mL, respectively [<span>12</span>]. Therefore, optimal dosing with limited dosing ranges is feasible for anti-IL-6R but not for anti-IL-6 ligands. For example, IL-6 receptor occupancy at steady-state trough levels was 98% or above with 200 mg of subcutaneous sarilumab every 2 weeks and 162 mg of tocilizumab weekly [<span>13</span>]. Another example is the failure of treatment in people with RA with extremely high serum tumor necrosis factor ","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the Risk of Frailty Progression Based on 5-Year Data in Patients With Rheumatoid Arthritis: A Multicenter Observational Study (T-FLAG)","authors":"Yoshifumi Ohashi,&nbsp;Mochihito Suzuki,&nbsp;Yasumori Sobue,&nbsp;Kenya Terabe,&nbsp;Shuji Asai,&nbsp;Shiro Imagama,&nbsp;Nobunori Takahashi","doi":"10.1111/1756-185X.70162","DOIUrl":"https://doi.org/10.1111/1756-185X.70162","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To examine risk factors for non-frailty rheumatoid arthritis (RA) patients progressing to frailty.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 304 RA patients with records for frailty assessment based on the Japanese Cardiovascular Health Study (J-CHS) criteria from 2020 to 2024 were included. Patients classified as non-frail (J-CHS scores 0–3) in 2020 were followed annually, and those who did and did not progress to frailty were categorized into the frailty progression (<i>n</i> = 100) and non-frailty progression (<i>n</i> = 204) groups, respectively. Risk factors for frailty progression were analyzed using the Cox proportional hazards model. Changes in DAS28-ESR and HAQ-DI between baseline and frailty progression were compared using a paired <i>t</i>-test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to the non-frailty progression group, the frailty progression group was older (62.9 vs. 68.5 years) and had a longer duration of disease (9.1 vs. 14.2 years), lower methotrexate (MTX) use (74.4% vs. 56.1%), higher mean DAS28-ESR (2.40 vs. 2.77), and higher HAQ-DI (0.17 vs. 0.45). Both groups had high biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) use rates (34.3% vs. 42.0%). Risk factors for frailty events included age ≥ 65 years (HR 1.86), duration of disease ≥ 10 years (HR 1.64), DAS28-ESR &lt; 2.6 (HR 0.64), HAQ-DI ≤ 0.5 (HR 0.45), and MTX use (HR 0.63). DAS28-ESR remained at a low disease activity level (baseline vs. frailty progression: 2.77 vs. 2.90), whereas HAQ-DI worsened at frailty progression compared to baseline (0.45 vs. 0.66).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Optimizing MTX use and achieving DAS/HAQ remission are crucial for preventing frailty. Non-medication-based approaches are also essential.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy and Safety of Hepatitis A Vaccine in Children and Young Adults With an Autoinflammatory Diseases on Canakinumab and Tocilizumab Treatments: A Prospective Observational Controlled Study","authors":"Kenan Barut,&nbsp;Mehmet Yildiz,&nbsp;Ömer Faruk Beşer,&nbsp;Fatih Haslak,&nbsp;Aybuke Gunalp,&nbsp;Elif Kılıç Konte,&nbsp;Esma Aslan,&nbsp;Ümit Gül,&nbsp;Nergis Akay,&nbsp;Amra Adrovic,&nbsp;Sezgin Sahin,&nbsp;Pelin Yüksel Mayda,&nbsp;Bekir Kocazeybek,&nbsp;Özgür Kasapçopur","doi":"10.1111/1756-185X.70196","DOIUrl":"https://doi.org/10.1111/1756-185X.70196","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Intro</h3>\u0000 \u0000 <p>In this prospective interventional study, we aimed to assess the efficacy and safety of the hepatitis A vaccine in patients with autoinflammatory diseases undergoing canakinumab and tocilizumab treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 24 patients with autoinflammatory diseases on canakinumab and tocilizumab treatments and 39 healthy children who were seronegative for hepatitis A were included in the study. All participants were vaccinated with 2 doses of inactivated hepatitis A vaccine at 6-month intervals. One month after the last vaccination, venous blood samples were collected from each participant, and the anti-HAV IgM and IgG titers were measured.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The patient group consisted of 19 patients with systemic juvenile idiopathic arthritis (sJIA) and 5 patients with cryopyrin-associated periodic fever. The mean age of the patient group and the healthy controls were 14.1 ± 3.7 and 12.4 ± 3.2 years, respectively. All patients with cryopyrin-associated periodic fever and 52.6% (10/19) of the patients with sJIA were on canakinumab. The remaining 9 patients (47.3%) with sJIA were using tocilizumab. Among sJIA patients, 15 were also on methotrexate, and 14 were on prednisolone. All of the participants were negative for hepatitis A serology. After two doses of hepatitis A vaccine, all the patients with autoinflammatory diseases (24/24) and 84.6% (33/39) of the healthy controls were detected as positive for anti-HAV IgG (<i>p</i> = 0.04). The mean anti-HAV Ig G titers of the patient group and the control group one month after the last dose of vaccination were 5.25 ± 1.49 IU/L and 10.5 ± 7.02 IU/L, respectively (<i>p</i> &lt; 0.001). Neither disease flares nor adverse effects related to vaccination were observed within the study period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Hepatitis A vaccine is effective and safe in children with autoinflammatory diseases on biologic therapy. Long-term follow-up data, including larger patient cohorts, are needed to draw a solid conclusion about the safety of hepatitis A vaccine in patients receiving canakinumab and tocilizumab therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143762124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital Gangrene as an Inaugural Presentation of Childhood Lupus","authors":"Abin Sheref Mohammed,&nbsp;Shivprasad Mohankumar,&nbsp;Sudheer Kumar Arava,&nbsp;Shivangi Dagar,&nbsp;Jyotsana Punj,&nbsp;Athimalaipet V Ramanan,&nbsp;Narendra Bagri","doi":"10.1111/1756-185X.70194","DOIUrl":"https://doi.org/10.1111/1756-185X.70194","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Markers of T Lymphocyte Activation in Children With Kawasaki Disease: An Experimental Study From North India","authors":"Paritosh Sharma,&nbsp;Pandiarajan Vignesh,&nbsp;Sanjib Mondal,&nbsp;Kanika Arora,&nbsp;Jitendra Kumar Shandilya,&nbsp;Jhumki Das,&nbsp;Rajni Kumrah,&nbsp;Kaushal Sharma,&nbsp;Jyoti Sharma,&nbsp;Deepti Suri,&nbsp;Amit Rawat,&nbsp;Surjit Singh","doi":"10.1111/1756-185X.70191","DOIUrl":"https://doi.org/10.1111/1756-185X.70191","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The exact pathogenesis of Kawasaki disease (KD) is unknown despite extensive research in the area. Several studies have also implicated CD8⁺ T lymphocytes in the pathogenesis of KD. However, studies on the activation status of T lymphocytes have shown conflicting results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective study, early (CD69) and late activation (HLA-DR) markers were assessed in T lymphocytes by flow cytometry. We assessed serum levels of soluble CD25 (sCD25) by enzyme-linked immunosorbent assay. We compared these activation markers between children with KD (<i>n</i> = 10), febrile controls (<i>n</i> = 9), and healthy controls (<i>n</i> = 10). Furthermore, we studied the HLA-DRA and HLA-DRB gene expression in subgroups of KD with or without coronary artery aneurysms (CAAs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A significantly higher percentage of CD69 in CD3⁺ and CD3 + CD4⁺ T lymphocytes was noted in KD and febrile controls compared with healthy controls. We found no significant increase in late activation marker HLA-DR in CD3, CD3 + CD4⁺, and CD3 + CD8⁺ lymphocytes between KD, febrile, and healthy controls. We observed higher levels of sCD25 in KD and febrile controls than in healthy controls. Longitudinal follow-up in KD showed a decreasing trend of CD69 expression in CD3 + CD8⁺ lymphocytes and sCD25 levels over time. HLA-DRA and HLABRB expression was comparable between children with CAAs and those without CAAs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study showed early but not late activation of T lymphocytes in children with KD. Markers of lymphocyte activation do fall with subsidence of systemic inflammation following intravenous immunoglobulin therapy in KD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 4","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tel Hashomer Camptodactyly Syndrome: Report on a New Case","authors":"Rafaela Nicolau,&nbsp;Cristina Rodrigues,&nbsp;Tiago Beirão,&nbsp;Rita Amorim,&nbsp;Francisca Guimarães,&nbsp;Sara Ganhão,&nbsp;Francisca Aguiar,&nbsp;Mariana Rodrigues,&nbsp;Iva Brito","doi":"10.1111/1756-185X.70195","DOIUrl":"https://doi.org/10.1111/1756-185X.70195","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 3","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Nutcracker Syndrome Triggered by Rapid Weight Loss in a Patient With Systemic Lupus Erythematosus","authors":"Chen Li,&nbsp;Yu-wei Wang,&nbsp;Han Sheng,&nbsp;Di Jin,&nbsp;Zi-xuan Shu,&nbsp;Ming Li,&nbsp;Sheng-Guang Li","doi":"10.1111/1756-185X.70190","DOIUrl":"https://doi.org/10.1111/1756-185X.70190","url":null,"abstract":"<div>\u0000 \u0000 <p>Nutcracker syndrome (NCS) is a rare vascular disorder characterized by compression of the left renal vein, typically causing hematuria, proteinuria, and flank pain. Although NCS is often linked with weight loss and anatomical variations, no previous reports have connected it to systemic lupus erythematosus (SLE). We describe a 44-year-old male with SLE who developed NCS after rapid weight loss, presenting with abdominal pain, hematuria, and proteinuria. Imaging confirmed left renal vein compression between the aorta and the superior mesenteric artery. This finding suggests that significant weight reduction in SLE may trigger NCS by altering retroperitoneal fat and vascular structures. A literature review reveals a consistent association between NCS and marked weight loss, as well as possible coexistence with other vascular compression syndromes, such as superior mesenteric artery syndrome. Clinicians should consider NCS in SLE patients with sudden weight changes to ensure timely diagnosis and prevent complications.</p>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 3","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Series: Effectiveness and Safety of Telitacicept in Chinese Patients With Primary Sjögren's Disease","authors":"Jiajia Wu,&nbsp;You Song,&nbsp;Weiwei Wang,&nbsp;Xujing Yuan,&nbsp;Rong Du","doi":"10.1111/1756-185X.70174","DOIUrl":"https://doi.org/10.1111/1756-185X.70174","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 3","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Study of the Diagnostic Value of Doppler Ultrasound Score in a Single Wrist Joint to Assess the Activity of Rheumatoid Arthritis","authors":"Zijing Chu,&nbsp;Zhixing Zhou,&nbsp;Muhammad Asad Iqbal,&nbsp;Zhongxin Zhang,&nbsp;Xian Wang","doi":"10.1111/1756-185X.70185","DOIUrl":"https://doi.org/10.1111/1756-185X.70185","url":null,"abstract":"&lt;p&gt;Rheumatoid arthritis (RA) is a generalized, chronic inflammatory disease involving multiple joints, characterized by joint swelling, tenderness, tendonitis, tenosynovitis, bone destruction, and it usually affects the surrounding joints, mainly including the small joints of the hands and feet [&lt;span&gt;1&lt;/span&gt;]. The 2018 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis recommend the clinical use of 28 disease activity scores in 28 joints (DAS28) to evaluate patients' mobility [&lt;span&gt;2&lt;/span&gt;]. Ultrasound, on the other hand, is more sensitive and reproducible than clinical assessment of joint inflammation [&lt;span&gt;3&lt;/span&gt;]. Power Doppler ultrasound (PDUS) can capture the changes in blood flow signals, and on the basis of gray scale ultrasound (GSUS), determine whether there is inflammation at the hyperplasia site, and can diagnose RA more accurately and early through the joint examination of the wrist joint by GSUS and PDUS [&lt;span&gt;4&lt;/span&gt;]. Nowadays, many studies at home and abroad use multi-joint ultrasound scores to diagnose and assess RA mobility, but the establishment of single-wrist ultrasound score as a standard for evaluating RA mobility is rarely reported. This study was approved by the Research Institution Review Committee of the First People's Hospital of Nantong, and the subjects voluntarily participated in the clinical study and signed the informed consent form.&lt;/p&gt;&lt;p&gt;RA patients who were admitted to the Department of Rheumatology and Immunology of Nantong First People's Hospital from 2021 to 2022 were randomly selected, a total of 100 RA patients were enrolled and divided into two groups based on disease activity: low/medium mobility and high mobility. Musculoskeletal ultrasonography was performed by using the French acoustic AIXPLORER ultrasound instrument and probe SL15-6 (frequency 6 ~ 15 MHz). Scan the mid-wrist, radial, and ulnar wrist of both wrist joints for diagnosis of synovitis, and scan the volar wrist flexor carpi radialis tendon, flexor pollicis longus tendon, flexor pollicis longus tendon, and dorsal carpal 1st to 6th chamber tendon for tendonization/tenosynovitis. Scan of the single wrist joint with an overall score, bone erosion, and joint effusion. The operator took pictures of all the scanned parts, and two sonographers with 5 years of experience in musculoskeletal imaging diagnosis could not obtain other clinical indicators of the patient, and the semi-quantitative score of the more severe lateral wrist joint under ultrasound conditions was completed. Synovitis (S) and tendon/tenosynovitis (T) were assessed with gray-scale score (GS) and energy Doppler score (PD), respectively, and bone erosion and joint effusion were assessed with GS. The Verio 3.0T high-field magnetic resonance imaging instrument of Siemens was used to perform MR noncontrast scan + enhanced examination on the wrist joint. The wrist with the higher VAS score was scanned by the VAS score [&lt;span&gt;1&lt;/span&gt;]. The MR non-contras","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 3","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70185","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Effect of Avacopan on Increasing ANCA Titres During Remission Maintenance in ANCA-Associated Vasculitis","authors":"Makoto Yamaguchi,&nbsp;Hirokazu Sugiyama,&nbsp;Hiroshi Kinashi,&nbsp;Kentaro Imai,&nbsp;Keisuke Kamiya,&nbsp;Takayuki Katsuno,&nbsp;Shogo Banno,&nbsp;Yasuhiko Ito,&nbsp;Takuji Ishimoto","doi":"10.1111/1756-185X.70183","DOIUrl":"https://doi.org/10.1111/1756-185X.70183","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 3","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}